---
title: "FOSUN PHARMA  Unit Fosun Antengene Raises Nearly RMB1B in Capital Increase, Prepares for Main Board Listing"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/289854905.md"
description: "Fosun Antengene, a subsidiary of FOSUN PHARMA, raised nearly RMB1 billion via a capital increase to prepare for its main board listing on the Hong Kong Stock Exchange. The deal involves issuing new shares representing ~12.15% of enlarged capital, with external investors contributing RMB418 million and the group RMB550 million. Fosun's stake will decrease slightly to 68.47%. Proceeds will fund daily operations, R&D expansion, production capabilities, and marketing."
datetime: "2026-06-16T02:45:49.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/289854905.md)
  - [en](https://longbridge.com/en/news/289854905.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/289854905.md)
generator: "portal-rs"
---

# FOSUN PHARMA  Unit Fosun Antengene Raises Nearly RMB1B in Capital Increase, Prepares for Main Board Listing

FOSUN PHARMA (02196.HK) -0.160 (-0.979%) Short selling $1.82M; Ratio 5.556% 's controlling subsidiary Fosun Antengene plans to issue new shares to four investors, representing approximately 12.15% of the total enlarged share capital after the capital increase, raising RMB968 million (same below). Among them, external investors plan to subscribe for a total of RMB418 million, while the group intends to contribute RMB550 million. The group's shareholding in Fosun Antengene is expected to decrease from about 70% to approximately 68.47%, and Fosun Antengene will remain a subsidiary within its consolidated financial statements.

As Fosun Antengene is currently preparing for a main board listing on the Hong Kong Stock Exchange, the option holders and the group have entered into a Supplemental Agreement to the Letter of Undertaking. The option holders agreed that the relevant options will be terminated starting from yesterday; however, if the listing plan of Fosun Antengene is terminated, the options will automatically resume in accordance with the agreement.

The proceeds from this capital increase will be used for the daily operations of Fosun Antengene and/or its controlling subsidiaries, including further expansion of its innovative R&D pipeline, strengthening core technologies, advancing the construction of production bases to enhance industrialized supply capabilities, and increasing marketing and commercialization investment in products already launched. (ha/a)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-06-15 16:25.)

### Related Stocks

- [06996.HK](https://longbridge.com/en/quote/06996.HK.md)
- [02196.HK](https://longbridge.com/en/quote/02196.HK.md)
- [600196.CN](https://longbridge.com/en/quote/600196.CN.md)

## Related News & Research

- [Antengene says Australia HREC clears Phase 1 ATTRACT trial of ATG-201 in B-cell autoimmune diseases](https://longbridge.com/en/news/296834857.md)
- [Fosun turns page after property writedowns, shifts focus back to growth](https://longbridge.com/en/news/297240299.md)
- [WUXI APPTEC  Sells 4.23% Stake in WUXI XDC, Cashes In HKD3.9B](https://longbridge.com/en/news/297217460.md)
- [WUXI APPTEC Reportedly Sells 2.6% Stake in WUXI XDC for Up to HKD2.4B](https://longbridge.com/en/news/297110148.md)
- [Livzon MABPharm wins China approval for Lecankitug psoriasis injection](https://longbridge.com/en/news/297167246.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**